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Chapter 1
Introduction
1.1 Motor Neuron Diseases
This heterogeneous group of diseases is characterized by a predominant affection of the mo-
tor neuron system. The chronic progression of these diseases can still hardly be influenced
by therapeutic intervention. The degeneration can affect the first motor neuron (central
paralysis), the second motor neuron (peripheral paralysis), or both systems in combina-
tion (Poeck and Hacke 2001). An affection of the first motor neuron is characterized by an
increase of the muscle tone and enhanced muscle reflexes, while an affection of the second
motor neuron is characterized by atonic paralysis and extinction of muscle reflexes (Trepel
2003). Spastic spinal paralysis is an example for a degeneration of the first motor neuron,
while spinal muscular atrophy (SMA) belongs to motor neuron diseases with degeneration
of the second motor neuron. The prevalent amyotrophic lateral sclerosis (ALS) shows the
nearly unique mixed pattern of a central and peripheral paralysis. One well-known ALS
patient is the astrophysicist Stephen Hawking, who develops fascinating theories on the
origin and evolution of galaxies, while being captured by his own body.
1.2 Spinal Muscular Atrophy (SMA)
There are different forms of SMA.The following study refers to the so-called proximal
spinal muscular atrophy, characterized by degeneration of the second motor neurons and
skeletal muscular atrophy. The disease is autosomal recessive and caused by a deletion
of, or mutations in, a single gene, the survival motor neuron 1 (SMN1) gene. After cystic
fibrosis, proximal SMA is the most common autosomal recessive disorder in humans, with
a carrier frequency of approximately 1 in 35 and therefore an incidence of 1 in 6000. It is
also the most common genetic cause of infant mortality (Monani 2005).
There are three types of proximal SMA ranging in severity from very severe (type I)
to intermediate (type II) to mild (type III) (Pearn 1980). Moreover, there are numerous
other less frequent forms of SMA with a different genetic background but similar phenotype
(Table 1). The leading symptoms of proximal SMA are a progressive predominant proximal
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Table 1: Modes of inheritance, gene location of the underlying mutation, phenotype and onset of the
different forms of SMA. Note that the three types of proximal SMA have the same genetic defect but
they differ in their phenotypes with lifespan ranging from under 2 years to normal. The other forms of
SMA have miscellaneous modes of inheritance and genetic background (from Monani, 2005, p 886;
reproduced with kind permission from Elsevier).
paresis, which appears always symmetric, and displays muscular fasciculation. The muscle
reflexes are abolished. Vegetative functions, like bleb and gut evacuations, are not generally
affected. Furthermore, no disturbance of the intelligence of patients is apparent. The
various forms of SMA are very different in their time course and prognosis (Poeck and
Hacke 2001).
SMA type I (Werdnig-Hoffmann) The acute type I form is characterized by severe,
generalized muscle weakness and hypotonia at birth or within the next 3 months. The
paralysis begins in the pelvic muscles and progresses from the extremities and from cranial
towards the facial muscles. The muscular weakness of the inspiratory muscles leads to
atelectasis, which promotes the development of infection and inflammatory processes.
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Death from respiratory failure or pneumonia occurs within the first two years (Poeck
and Hacke 2001).
SMA type II (intermediate - chronic form) The onset of the disease is later than
in type I, at an age between 6 and 18 months. The type II patients learn to sit and mostly
to crawl while walking is impossible (Kunze, 1999). Although most patients become older
than two years pulmonary complications are leading to an early death (Kunze, 1999).
SMA type III (Kugelberg-Welander) The mildest form of proximal SMA can be
symptomless until the early adulthood. The onset is mostly within ages 2 and 17 years.
A proximal weakness of the legs starts after an initially normal motor development. This
might first be noticeable through difficulties in climbing stairs and standing up. In the
later disease course most patients become dependent on a wheel chair. The life span is not
considerably shortened.
1.3 The Genetic Principles of Proximal SMA
All three forms of proximal SMA are autosomal recessive. Regardless of the disease severity,
95% of all patients carry a deletion in a gene containing nine exons that localizes to
chromosome 5q11.2-13.3. This gene is termed the telomeric survival of motor neuron
gene (SMN1). The remaining 5% carry small mutations in the gene. In humans the
SMN1 gene lies within a 500 kb inverted-duplicated region. Through the duplication of
this region the centromeric half contains an almost identical copy gene, SMN2 (Lefebvre
et al 1995). SMA patients lack the telomeric SMN1 gene, but they have at least one
copy of SMN2. This, however, produces only around 10% functional SMN protein and
therefore can not compensate for the lack of the former. The difference in expression
between the two genes is due to a translational silent single nucleotide (C to T) transition
inside SMN2 exon 7. This critical transition leads to an alternative splicing of the SMN2
gene, resulting in a shortened gene product (SMN ∆Ex7) lacking exon 7. This makes
a genetic diagnosis of SMA relatively straightforward, based on a simple PCR reaction
(Dreesen et al 1998). Due to the shorter length of the SMN2 transcript compared to the
SMN1 transcript both genes can be distinguish from each other through gel electrophoresis.
The SMN ∆7 isoform is unstable and rapidly degraded. While the SMN1- transcript is
almost 100% translated to functional full-length protein (FL-SMN), only 10% of SMN2
transcript translated to FL-SMN protein. Patients with a deletion in the SMN1 gene,
therefore, express insufficient levels of functional FL-SMN protein. Figure 1 shows the
molecular basis of SMA: transcription and translation of SMN1 and SMN2-gene as well as
the resulting amounts of protein (Monani 2005).
The number of SMN2 genes varies in the population from 1 to 6 copies. The greater
the number of SMN2 genes, the more FL-SMN protein is produced and the milder is the
disease phenotype (McAndrew et al 1997) (Feldkötter et al 2002). This explains the range
in severity among SMA type-I, type-II, and type-III patients. A direct correlation between
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Figure 1: The molecular basis of the proximal spinal muscular atrophy depicting the two major
genes involved in the disease, SMN1 and the modifier SMN2. Almost 100% of the SMN1 transcript is
translated to functional full-length SMN protein while only 10% of the SMN2 transcript is translated
to FL-SMN. In SMA patients homozygous deletion or mutation in the SMN1 gene leads to insufficient
levels of SMN protein for survival and maintenance of motor neurons. The amount of FL-SMN protein
levels in patients therefore determines the severity of the disease, depending on the number of SMN2
copies ( Monani et al. 2005 , p 887; reproduced with kind permission from Elsevier).
the amounts of full length SMN-expression and severity of the phenotype demonstrates
that SMA is due to a classical gene dose effect.
In essence, SMA results from low levels of the FL-SMN protein.
1.4 The FL-SMN Protein
1.4.1 Assembly and Distribution of the FL-SMN Protein
The FL-SMN protein contains 294 amino acids and has a molecular weight of 38 kilo Dal-
ton (kDa). It is ubiquitously expressed and does not exhibit homology to any previously
identified protein. The necessity of the SMN for cellular survival and function has been
proven in the following organisms and cell types: human, mouse, chicken, DT40 cells, -
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Figure 2: Schematic diagram of SMN showing coding exons and the relative localization of selected
domains with known functions. In SMN2 exon 7 is spliced out resulting in truncated protein lacking
the C-terminal- most 16 amino acids ( (Briese et al 2005), p 947; reproduced with kind permission
from John Wiley and Sons).
drosophila melanogaster, caenorhabditis elegans, and schizosaccharomyces pombe, indicat-
ing that SMN is essential for viability of all eukaryotic organisms (Miguel-Aliaga et al 1999;
Hannus et al 2000; Paushkin et al 2000; Wang and Dreyfuss 2001). One central question
around this protein is why defects in a ubiquitously expressed protein have such a selective
effect on motor neurons and corresponding muscles.
The C-terminal region of the SMN-protein contains a region for self-oligomerisation
encoded by exon 6, which contains numerous tyrosin-glycin pairs (Lorson et al 1999). This
is flanked by a central evolutionary highly conservative tudor domain, encoded by exon 3,
which contains 53 amino acids and is important for the interaction between SMN and the
Sm-proteins (Bühler et al 1999). Further interaction domains and a schematic illustration
of the SMN-protein are shown in Figure 2.
Within one cell SMN can be found in the cytoplasm as well as in the nucleus (Liu
and Dreyfuss 1996). The distribution of SMN in the cytoplasm appears diffuse in all cells
studied. Only in muscle cells is SMN existent in large cytoplasmic aggregates (Liu and
Dreyfuss 1996) (Burlet et al 1998). In the nucleus SMN appears as 0,1-1 µm large, dot-like
structures. These structures were often found to colocalize with coiled bodies and were
therefore termed gems (gemini of coiled bodies). The name coiled bodies has been recently
replaced by the name cajal bodies (Gall et al 1999). Cajal bodies are known to be rich
in factors involved in the transcription and processing of many types of nuclear RNAs.
The close interaction of gems with cajal bodies indicates that gems are also involved in
RNA-processing (Liu and Dreyfuss 1996). Beside the localization in gems SMN is also
directly localized in cajal bodies in cultured cells and primary neurons (Carvalho et al
1999). In HeLa cells the assembly of the coiled bodies is disrupted due to the depletion
of SMN (Girard et al 2006). Furthermore, the group of Carvalho could show that SMN
in cajal bodies colocalize with small nuclear ribonucleoproteins (snRNPs). In this study
the majority (>85%) of cells studied contained SMN only in cajal bodies, while no gems
could be identified (Carvalho et al 1999). Depending on the tissue SMN is expressed
in different amounts (Coovert et al 1997) (Burlet et al 1998). Particularly high levels
of the protein are found in the spinal motor neurons, apparently the most profoundly
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affected cells in SMA patients. Furthermore, different studies in human tissue (muscle,
heart, kidney and brain) show a clear reduction of SMN-expression after birth (Burlet
et al 1998). Interestingly, it is found that the intracellular distribution changes during the
normal CNS-development. There is a shift from SMN being localized more in the nucleus
during early stages of development towards an accumulation in the cytoplasm, especially
in axons of motor neurons (Giavazzi et al 2006).
The amount of SMN is reduced in all reviewed tissues of SMA patients (Burlet et al
1998), with patients with SMA type I having smaller amounts of SMN protein than type II
or type III patients (Coovert et al 1997) (Lefebvre et al 1997) (Burlet et al 1998). The spinal
cord, with an almost complete absence of FL-SMN protein in type I patients, is especially
affected, while the amount of SMN in lymphocytes and muscle tissue is only moderately
reduced. Although in SMA mostly lower motor neurons are affected, a reduction in all
reviewed tissues is detectable (Jablonka et al 2007). However SMA patients develop in
the first line motor neuron degeneration and muscular atrophy (Jablonka et al 2007). In
order to shed light on the selective effect of SMN on the nervous system several groups
studied in particular the distribution of SMN in motor neurons. Béchade et al (1999)
could for the first time demonstrate that SMN is located in the proximal part of dendrites,
where it is associated with microtubules. One year later, another research group also came
to the conclusion that the SMN is associated with elements of the cytoskeleton in spinal
dendrites and axons, in particular during the early postnatal development (Pagliardini et al
2000). The discovery of SMN in axonal compartments led to the assumption that SMN
is actively transported. Recent studies showed granular accumulations of SMN in axons
of motor neurons. They demonstrated that the transport of SMN over longer distances
is microtubules-dependent, while for shorter distances microfilaments are required (Zhang
et al 2003). SMN is also found in the growth cones of motor neurons (Rossoll et al 2003).
1.4.2 The SMN-Complex
SMN is the central component of a large oligomeric complex, the so-called SMN-complex
(Meister et al 2001) (Gubitz et al 2004). Already in 1996 Liu and Dreyfuss showed that
SMN binds amongst others to itself, to the RGG-rich region of hnRNP U, and to fibrillarin.
One year later this group identified the SMN interacting Protein1 (SIP-1), which was later
termed gemin2. Until now seven more gemins have been identified. Figure 1 shows a
scheme of all seven interacting proteins called gemin 2-7.
This complex has been postulated to function as an “assemblysome” important for
snRNP biogenesis and pre-mRNA splicing, which will be described in the next section.
The binding partners of the SMN-complex can also appear independently from each other.
A recent study showed that gemin2 forms a complex with SMN including no other gemin
proteins. This leads to the assumption that the pair SMN-gemin2 is the smallest available
subunit. Overall a multitude of other proteins has been identified, which directly interact
with SMN and/or gemins, although they are not integral components of the SMN-complex.
To these proteins belong among others, the Sm- and Lsm-proteins of the small ribonucleo-
protein family (snRNPs) (Liu et al 1997); (Bühler et al 1999) (Friesen and Dreyfuss 2000),
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Figure 3: Schematic illustration of the SMN-complex with known components (taken from (Carissimi
et al 2006). SMN is interacting directly with gemin2, gemin3, gemin4 and gemin5 and gemin7 (Liu
et al 1997); (Charroux et al 2000) (Gubitz et al 2004), while gemin4 binds over gemin3 (Charroux
et al 2000). For the interaction of gemin6 with SMN-complex is Gemin7 required. Gemin8 binds to
Gemin6 and Gemin7 on the multiprotein complex ( (Carissimi et al 2006), p. 8134; reproduced with
kind permission from the author).
the helicase A (Pellizzoni et al 2001) and hnRNP Q (Mourelatos et al 2001).
The exact implication of these interactions remains to be determined. However the
knowledge of these interactions may shed light on additional neuron specific functions of
SMN, which may explain why reduced SMN levels have relatively little impact on cells
other than motor neurons.
1.4.3 The Role of SMN in SnRNP Biogenesis and pre-mRNA
Splicing
The most extensively documented function of the SMN has been the so called housekeeping
role in providing small ribonucleoproteins, which are the main components of the spliceo-
some. One essential step of posttranscriptional processing of the pre-mRNA to mature
mRNA is the splicing of pre-mRNA in the nucleus before being exported to the cytoplasm.
During splicing the noncoding introns are removed from the pre-mRNA and the protein-
encoding exons are linked to each other. This process is catalyzed by the spliceosome. The
main components of the splicesomes are U snRNPs (uridine-rich small nuclear ribonucleo-
proteins) (Will and Lührmann 2001). Each snRNP contains seven Sm-proteins plus one or
two small nuclear RNAs (snRNA U1, U2, U4/U6 and U5). The role of the SMN-complex
in the assembly of splicesomal U snRNPs U1, U2, U4/U6 and U5 in the cytoplasm has
been studied in detail (Fischer et al 1997); (Selenko et al 2001); (Jablonka et al. 2002);
(Winkler et al 2005); (Kolb et al 2007). The SMN-complex builds the U snRNPs by load-
ing the Sm-proteins in a well defined order onto the U snRNA (Pellizzoni, 2007). In this
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Figure 4: The mode of action of the SMN and PRMT complexes. The Sm-proteins are newly
synthesized by the cell and bind to the PRMT5-complex (1). This adds methyl groups to the Sm-
proteins, which cause their handing-over to the SMN-complex (2). The SMN-complex subsequently
transfers the Sm-proteins to a nuclei acid, called U snRNA (3), thereby forming U snPNP, a subunit
of the spliceosome. SMN- and PRMT5-complexes may then enter into a new cycle ( Fischer et al.
1997, p. 750; reproduced with kind permission from the author).
function the SMN-complex is strictly controlled by a further protein assembly called the
PRMT5-complex. Figure 4 shows the sequential course of this clustering reaction towards
U snRNPs.
This process takes place in the cytoplasm. The snRNPs are then imported to the
nucleus, where they are often found together with SMN-complexes in cajal bodies, where
they undergo further maturation processes before they take up their function in pre -RNA
splicing.
The role of SMN in snRNP biogenesis and pre-mRNA splicing has been most extensively
documented (Meister et al 2000; Hannus et al 2000). However, it still remains unknown
whether SMA and the motor neuron phenotype are a direct consequence of a disruption
in snRNP biogenesis and pre-mRNA splicing.
A defect in a function as universal as snRNP biogenesis and pre-mRNA splicing is
likely to affect all tissues equally. There are basically three schools of thought to explain
why defects in a ubiquitously expressed protein may have such a selective effect on motor
neurons.
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(i) Considering that low levels of SMN lead to a general defect of mRNA splicing, the
tissue-specific nature of SMA could be explained by the fact that motor neurons
simply have lower tolerance for depleted SMN levels, being large, high-energy requir-
ing cells. However, a lack of an adverse effect on other large, high-energy requiring
cells, such as cortical motor neurons and sensory neurons makes this a questionable
hypothesis.
(ii) Another possibility would be that the unique sensitivity of affected motor neurons in
SMA is a result of aberrant splicing of one or more RNAs, which are critical for the
appropriate functioning of these cells. However, such RNAs have yet to be identified.
(iii) The SMN may have additional motor neuron specific functions besides its role in
snRNP biogenesis and pre-mRNA splicing. Studies confirming this school of thought
will be discussed in the next section.
1.4.4 Motor Neuron Specific Function of SMN
The main feature distinguishing neurons from other cell types is that they possess den-
drites and axons that convey messages from one neuron to another or target muscle cells
by chemical and electrical processes. This feature implies that cargo has to be transported
over long distances in order to secure sustainability and growth of neurons. Several lines of
evidence support additional neuron-specific functions of SMN. The hypothesis that SMN
has a neuron-specific function firstly emerged from the observations demonstrating accu-
mulation of SMN protein in the axon and growth cones of neurons specifically in cells in
vitro (Fan and Simard 2002) and anterior horn cells in vivo (Tizzano et al 1998). These
observations have been fostered by experiments identifying the presence of SMN-containing
granules within the neurites of chick cortical neurons and rat spinal motor neurons (Figure
5), that associate with microtubules and exhibit bidirectional movement between the cell
body and the growth cone (Zhang et al 2003) .
Moreover, it is well established that SMN can bind RNA (Lorson and Androphy 1998)
(Bertrandy et al 1999) and ribonucleoprotein particles (Jones et al 2001); (Liu and Dreyfuss
1996); (Mourelatos et al 2001).
These findings lead to the assumption that SMN may be involved in the transport of
specific mRNAs to the growth cone in response to local cues during development. Rosoll
and colleagues reported that SMN and its binding partner hn-RNP R modulate axon
growth cones. They finally discovered that SMN and its hnRNP are involved in the pro-
cessing and localization of β-actin mRNA to the growth cones of developing motor neurons
(Rossoll et al 2003). Reduced growth cone size, lower β-actin levels and shorter neurites
in primary motor neurons from SMA mice add further weight to this line of thought. The
role of actin in the SMA disease will be discussed in a following section.
Recent studies could show that SMN directly binds to the alpha-subunit of the vesi-
cle coat protein ’coat protein I’ (COPI). This subunit, alpha-COP, is Golgi associated
and co-immunoprecipitates with SMN, small nuclear ribonucleoportein-associated assem-
bly factors and β-actin mRNA. This observation leads to the proposal that neurons utilize
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Figure 5: A chick cortical neuron stained with an antibody against SMN showing abundant nucleo-
cytoplasmic staining as well as the presence of granules (arrows) within neurites and the growth cone.
The granules, RNP particles, are found associated with microtubules, indicating movement along the
axon. This supports the idea of a motor neuron specific function of the SMN protein ( (Monani 2005),
p. 889; reproduced with kind permission from Elsevier).
the Golgi associated COPI vesicles to deliver cargos necessary for motor neuron integrity
and function (Peter et al 2011). Thus, another study adds further weight to the hypothesis
that mutated SMN interferes with the transport of cargo in the axon, which might provide
an explanation of the neuron-specific nature of SMA.
1.5 Mouse Models of SMA
Animal models can shed considerable light on the pathogenesis and mechanisms of their
respective human disease. Since the SMN mutations were first identified as responsible
of SMA, numerous organisms have been manipulated in order to generate animal models
of SMA. In the following, the approach leading to the mouse model we used for our ex-
periments will be explained. Several problems had to be circumvented before obtaining a
suitable mouse model.
The identification of the murine homolog of the SMN gene (Smn) (DiDonato et al
1997) made it possible to knock it out (Schrank et al 1997). However, humans are the
only species with an SMN2 gene and all SMA patients carry at least one intact SMN2
gene. A complete knock out in mice, in other words a complete lack of the SMN protein,
is embryonically lethal and therefore did not result in a useful mouse model, but provided
evidence that Smn is an essential gene (Schrank et al 1997). This is not surprising, given
the fact that in SMA patients the SMN1 gene is also deleted or mutated but the SMN2
gene is still producing small amounts of FL-SMN protein.
One approach taken to overcome the embryonic lethality in Smn -/- mice was to in-
troduce the SMN2 gene into this genetic background (Monani et al 2000). This strategy
showed that the phenotype depends on the SMN2 transgene copy number. The introduc-
tion of eight copies of SMN2 completely rescued the SMA phenotype, two copies resulted
in SMA mice that die at 5 days of age (Hsieh-Li et al 2000); Monani et al. 2000) and one
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copy was embryonically lethal (McGovern et al 2008). The most abundant gene product of
SMN2 is called SMN∆7, its name describing the fact that the resulting protein is missing
the information of exon 7 due to alternative splicing.
To test whether SMN∆7 is beneficial or detrimental in SMA, Le and colleagues (Le
et al 2005) created transgenes expressing this SMN isoform and introduced them into the
severe SMA genetic background with two SMN2 copies.
They could demonstrate that an increase in SMN∆7 has a positive effect on the survival
of SMA mice by extending their lifespan from 5.2 ± 0.2 to 13.3 ±- 0.3 days (Le et al 2005).
This phenotype with specific motor defects, and mice that survive up to 14 days turned out
to be a very suitable model for experiments and were therefore also used in our experiments.
Our mouse lines were kindly provided by Dr. A. Burhes and the Ohio State Univer-
sity. The experimental mice were obtained by breeding pairs of SMA carrier (Smn+/-;
SMN2+/+; SMN∆7 +/+) on a FVB/N background.
1.6 Neuro Muscular Junction (NMJ) Pathology in
SMA
1.6.1 Synaptic Vesicles
Synaptic vesicles allow the communication between neurons and other cells through re-
leasing neurotransmitter, at the NMJ acetylcholine, into the synaptic gap, as chemical
response to the electrical impulse arriving at the nerve terminal. Vesicles are constantly
recreated and grouped into three pools: the readily releasable pool, the recycling pool, and
the reserve pool. The vesicles of the readily releasable pool are docked to the cell mem-
brane, making them the first group of vesicles to be released on stimulation. The recycling
pool is defined as those vesicles that maintain release upon (physiological) moderate stim-
ulation. The majority of vesicles (typically ∼ 80-90%) belong to the reserve pool from,
which release neurotransmitter only during intense stimulation (Rizzoli and Betz 2005).
Figure 6 illustrates this three-pool model.
Several functional studies at the NMJ in SMA mice lead to the question whether there
is a disruption regarding synaptic vesicles in SMA mice. Kong and colleagues measured
a two-fold reduction of the evoked endplate currents (EPCs). The EPCs depend on the
number of fused vesicles and the muscle response to the transmitter released from a single
vesicle. The spontaneous miniature EPC (MEPC), defined as muscle response to one single
vesicle, was found to be normal, indicating that a decreased number of fused vesicle leads
to the reduction of the EPCs (Kong et al 2009).
In agreement with this study it was found that the kinetics of the postsynaptic poten-
tials are slowed and evoked neurotransmitter release is decreased by approximately 55%
in Transverus Abdominus (TVA) muscle (Ruiz et al 2010). Indeed electron microscopy
images of the NMJ in TVA showed that individual synaptic vesicles within presynaptic
terminals had normal diameters and morphology, but overall density of synaptic vesicles
within the presynaptic terminal area was reduced by 56%, while the number of docked
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Figure 6: “The classic three-pool model. The reserve pool makes up ∼80–90% of the total pool,
and the recycling pool is significantly smaller (∼10–15%). The readily releasable pool (RRP) consists
of a few vesicles (∼1%) that seem to be docked and primed for release”. Figure and caption from
(Rizzoli and Betz 2005), p. 58; reproduced with kind permission from Nature Publishing Group)
vesicles, defined as those within 20 nm of the membrane, was only reduced by 32% (Kong
et al 2009). In contrast, in diaphragm no significant difference in vesicle number was found
(Kariya et al 2009).
To expand the perspective of the amount and distribution of synaptic vesicles (SVs) in
SMA mice, we explored both total area of the terminal covered by SVs and the SVs spatial
organization through fluorescent microscopy. First we undertook this study in TVA, a
postural muscle of the anterior wall innervated by lower intercostal nerves. This muscle is
known to be severely affected in the disease.
Additionally, we studied SVs in Levator Auris Longus muscle (LAL) from the dorsal
surface of the head, innervated by the facial nerve. These studies allowed us to quantify pre-
and postsynaptic pathology in muscle groups from two anatomical regions of the mouse
and to compare pathologies in predominately slow-twitch (TVA) versus fast-twitch (LAL).
Two further characteristics render the LAL muscle an interesting object of study: First, the
LAL has two constituent muscle bands, among which the caudal band is known to be more
affected in the disease than the rostral band (Murray et al 2008). After a comprehensive
comparison between the rostral and the caudal bands, it was shown that the two bands
differ in their “Delayed Synapsing” (DeSyn) and “Fast Synapsing” (FaSyn) characterictis
(Murray et al 2008). It is therefore likely that selective vulnerability is due to the FaSyn
characterictics, dominant in the caudal band. These two classes, DeSyn and FaSyn, differ
in the focal AChRs clustering, the alignment of presynaptic nerve with AChRs and the
alignment of schwann cells. In FaSyn muscles, this focal organization process is achieved
in less than 1 day, whereas in DeSyn muscles up to 5 days are required (Murray et al
2008). Experimentally these two classes can be distinguished by their reaction to paralysis
with botulinum toxin A. While NMJs conforming to a DeSyn phenotype have been shown
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to undergo dramatic collateral sprouting, FaSyn NMJ remains largely unaffected (Murray
et al 2008).
Second, postsynaptic terminals have been described to mature almost at the same pace
as in control mice (Murray et al 2008). This allows us to assess the question to what
extent pre-and postsynaptic phenotypes are interrelated by proving whether the pathology
regarding SVs found in TVA is also found in LAL.
The question how deficiency of SMN protein can contribute to the observed abnormal-
ities of synaptic vesicles will be addressed in the discussion part.
1.6.2 Mitochondria
Mitochondria are organelles of elaborate structure, that in addition to supplying cellu-
lar energy and producing reactive oxygen species (ROS) have significant roles in calcium
homeostasis and apoptosis. At the presynaptic side they regulate intraterminal Ca2+ lev-
els, providing an especially important buffering action during trains of action potentials
(David and Barrett 2000). Exploring the neurotransmission of severe SMA revealed that
asynchronous neurotransmitter release is increased by ∼ 300% compared to the wild type
(Ruiz et al 2010).
Presynaptic terminals release neurotransmitter at rest (spontaneous release), upon a
single action potential (synchronous evoked release), and during intraterminal Ca2+ accu-
mulation resulting from prolonged electrical stimulation (asynchronous release). Therefore,
the mentioned increase of asynchronous release indicates an anomalous augmentation of
intraterminal bulk Ca2+ in SMA mice. A possible explanation for this augmentation is
a decreased Ca2+ reuptake by mitochondria during trains of action potentials (Ruiz et al
2010).
Mitochondria dysfunction is known to be involved in many neurodegenerative diseases,
however little is known about the role of mitochondria in SMA pathogenesis. Mitochondria
are briefly mentioned in two electron microscopy (EM) studies on P14 SMA mice. The
study in diaphragmatic muscle showed that presynaptic mitochondria are decreased in size
but not in numbers (Kariya et al. 2008). In contrast, another research group demon-
strated in Tibiales Anterior muscle a reduced density of mitochondria, while mitochondrial
morphology was normal (Kong et al 2009).
To study the density, reliability, and spatial distribution of mitochondria in Transversus
Abdominal muscle (TVA) at P14 under the confocal microscope, we used Mito Tracker , a
cell-permanent fluorescent dye that is sequestered by functioning mitochondria. Moreover
we explored the spatial relationship between Mito Tracker spots and SV clusters; reflecting
the two main organelles of the presynaptic compartment, for which actin serves as a track
for short-range transport (Langford 2002).
1.6.3 F-Actin
Actin is one of the most abundant proteins in eukaryotic cells. Actin is the monomeric
subunit of microfilaments known as globular actin (G-actin). G-actin subunits assemble
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Figure 7: Simplified model of how SMN depletion impacts the regulators of actin cytoskeletal
dynamics and thereby causes in motor neuron degeneration ( (Bowerman et al 2009) p. 72; reproduced
with kind permission from author).
into long filamentous polymers called F-actin.
In neurons, actin-filament plays an important role in multiple functions such as axon
initiation, growth, guidance, and branching during neuron development. In order to secure
sustainability in neurons, cargo has to be transported over long distances. The “dual trans-
port model” was proposed in which microtubule-based motors ensure long-range axonal
transport, whereas short-range movement of organelles such as vesicle and mitochondria at
nerve terminals and subcortical plasma membrane regions depends primarily on actin-based
myosin (Langford 2002). In addition to these functions, the F-actin-based network (Hi-
rokawa and Takeda 1998) may participate in creating a scaffold for SV clustering, and/or in
supporting ordered vesicle mobility. Moreover, it has been suggested that F-actin anchors
synaptic vesicles to AZs by a labile link formed with synapsin, a vesicle protein (De Camilli
et al 1990); Greengard et al. 1993)
Several lines of evidence suggest that a deregulation of actin plays an important role in
SMA pathogenesis. SMN with its binding partner hnRNP R has been shown to interact
with β-actin mRNA and mediates the transport along the axon. A decrease in actin pro-
tein content in growth cones of SMN-deficient motor neurons in culture and reduced axon
growth adds further weight to this line of thoughts (Rossoll et al 2003). Additional SMN-
deficient PC12 cells have increased levels of neuronal profilin IIa protein, accompanied by
a decrease in levels of plastin3 (Bowerman et al 2009). This is leading to an inappropriate
activation of the Rho/ROCK pathway. RhoA is a small GTPase that plays an important
role in the regulation of actin cytoskeletal dynamics, which is essential for a balanced equi-
libration between actin depolymerization and filament stabilization (Luo et al 1997). In
neurons, by signaling through various pathways, RhoA mediates neuronal growth, forma-
tion, polarization, regeneration, branching, pathfinding, guidance, and retraction (Govek
et al 2005).
Given that actin might play a key role in SMA pathogenesis, we wanted to explore
further its content and distribution relative to SVs in TVA motor terminals of SMA mutant
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mice. F-actin was revealed by fluorescent Phalloidin-Alexa 647, which binds to all isoforms
of F-actin, but not to monomeric actin (Wulf et al 1979).
1.6.4 The Questions and Objectives of this Study
Previous research about spinal muscular atrophy using animal models provided important
insights regarding the pathomechanisms of this disease.
Rosoll and colleagues (2003) could show in motor neurons in culture that SMN together
with its binding partner heterogeneous nuclear ribonucleoprotein (hnRNP) R interacts with
the β-actin mRNA and mediates its transport along the axon. Among others, this study
provided evidence for a motor neuron specific function of SMN and indicated that actin
plays an important role in SMA pathogenesis.
Short-range movements of organelles, such as vesicles and mitochondria, belong, among
others, to the processes mediated by actin in motor neurons (Langford 2002). Moreover the
F-actin-based network may participate in creating a scaffold for synaptic vesicle clustering
(Hirokawa et al 1989) and it has been suggested that F-actin anchors synaptic vesicles to
AZs by a labile link formed together with synapsin, a vesicle-associated protein (De Camilli
et al. 1990; Greengard et al. 1993).
Functional studies at the NMJ of SMA mice revealed that evoked neurotransmitter
release is decreased by approximately 55% in TVA muscle, indicating a decreased number
of fused vesicles. On the other hand asynchronous release is increased by ∼ 300% due to an
anomalous augmentation of intraterminal bulk Ca2+ in SMA mice. A possible explanation
of this augmentation is a decreased Ca2+ reuptake by mitochondria during trains of action
potentials (Ruiz et al 2010).
The work described here has the aim to explore the amount and organization of Synap-
tic Vesicles (SVs), mitochondria, and actin in nerve terminals of SMA mice compared to
controls, in order to provide morphological evidence for the observed disturbed neurotrans-
mission at the NMJ of SMA mice. Moreover, it is my aim to gain insight into the question
whether a deregulation in actin dynamics provides a possible link to abnormalities observed
in SMA pathogenesis.
All experiments regarding SVs, mitochondria and actin were done with TVA muscle of
14 days (P14) old mice in a mouse model of a severe form of this disease.
The study about SVs has been extended in the following aspect:
To get insight into the maturation process in SMA disease, the distribution of SVs were
studied additionally in seven days (P7) old mice, both in TVA and levator auris longus
(LAL) muscle. The LAL consists of a rostral and a caudal band. The caudal band is known
to be more affected than the rostral band in the disease (Murray et al 2008). This allowed
me to study SVs for three different muscle conditions at P7 and P14. Another characteristic
of the LAL is that the postsynaptic terminals have been described to mature almost at
the same pace as in control mice, while the presynaptic morphology shows abnormalities
in P5-P6 SMN deficient mice (Murray et al 2008). It was my aim to test in LAL muscle
whether SVs abnormalities occur also in the absence of a postsynaptic pathology to gain
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insight into the question how much pre- and the postsynaptic phenotypes are interrelated
in SMN deficient mice.
In particular the following aspects will be quantified:
1. Synaptic Vesicles
(a) Total area of SV clusters
(b) Mean area of a single SV cluster
(c) Number of SVs clusters
2. Mitochondria
(a) Total area of Mito Tracker spots
(b) Mean area of a single Mito Tracker spots
(c) Number of Mito Tracker spots
3. Organization of Synaptic Vesicles and Mitochondria within the nerve terminal





SMA mouse lines were kindly provided by Dr. A. Burghes (Ohio State University, Ohio,
USA) and are presently available in the Animal House in Seville. Experimental mice
were obtained by breeding pairs of SMA carrier mice (Smn+/-;SMN2+/+;SMN∆7+/+)
on a FVB/N background. Mice were housed, handled, and bred in accordance with the
regulations of the E.U. for animal care and use.
2.1.2 Equipment
Genotyping
Centrifuge Eppendorf 5415 D
Multipipette Eppendorf plus
Thermocycler Biometra TGradient
UV Transilluminator Vpland M 15
Surgery
Mayor scissors F·S·T stainless (Germany) 14060-11
Forceps F·S·T stainless (Germany) 14022-12
Microsurgical scissors Nopa CE Germany Stainless AC778/02
Surgical Blade Steriler CE 0434
18 2. Materials and Methods
Immunocytochemistry
Microscope Slides Menzel Glaeser
Coverslip Menzel Glaeser
Orbital Shaker Biosan 0S-20
Plates Cellstar
Vapor Pressure Osmometer Wescor 5500
pH Meter Crison Basicco
Scale Mettler PJ360
Microscopy
Stereoscopic Zoom Microscope Nikon SMZ1500





Alkaline Lysis Reagent (25mM NaOH; 0.2 mM EDTA)
Neutralization Reagent 40mM Tris-HCL adjusted to pH)
Ethidium Bromide Sigma 160535
Primers
Neo B Primer Sigma VC00021
A2R Primer Sigma 700023




Taq 5U Biotools 10043
Solution and Buffers
PBS Buffer 10X Biotools 10044
Electrophoresis Buffer 192 mM Glycine, 0.1% SDS, 25mM Tris-HCl, pH 8.3
SDS-Sample Buffer 0.125 M Tris-HCl, pH 6.8, 4% SDS, 0.15 M DTT
20% Glycerol, 0.01% Bromphenol blue
2.1.4 Immunocytochemistry
Chemicals
Paraformaldehyde (PFA) Sigma-Aldrich, CAS 30525
Phosphate Buffered Saline (PBS) Sigma-Aldrich, EC 231-834-5
Albumin from Bovine Serum (BSA) Sigma-Aldrich, EC 232- 936- 2
Glycine Sigma-Aldrich, EC 200-2722
Slowfade Gold Antifade Reagent Invitrogen 586012
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1.25 µl/ml snake toxin Invitrogen L2911
α-Bungarotoxin
Rhodamine
1.25 µl/ml snake toxin Sigma T0195
Alexa flour 647
phalloidin
25µl/ml mushroom toxin Invitrogen A22287
Table 2: Summary of reagents used for immunostaining.
Solutions and Buffers
Hepes solution:
• 145 mM NaCl
• 5 mM KCl
• 2 mM CaCk2
• 1 mM MgCl2
• 15mM glucose
• 10 mM Hepes.
NaOH was used to adjust the pH between 7.35 and 7.4. The osmolarity was adjusted
between 300 and 310 mmol/kg by using an osmometer.
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2.2 Methods
2.2.1 Genotyping
SMA mice could be distinguished from wild type mice through clinical observation; how-
ever, all mice were genotyped for confirming their genetic characteristic.
Visual and clinical Identification of SMA The SMA mice (∆7) are smaller in size
and appear weak and less active compared to WT mice. Further identification was done
through the righting reflex test: when turned onto there back SMA mice showed some
latency in righting themselves.
Marking and caudal biopsy Five days after birth each mouse received an individual
identification number by cutting a fingertip. Through this mark the mice could be identified
before the experiment. The PCR genotyping was done using tail DNA.
DNA Extraction To lyse the cells, the tissue samples from caudal biopsy were cen-
trifuged for 30 sec at 13.000 rpm with 50 µl added alkaline lysis reagent and then incubated,
first for 30 min at 65◦C, followed by 15 min incubation at 98◦C. After lysis, the samples
were placed on ice for 1 min and treated with 50 µl Neutralizing Reagent. To separate the
DNA from the rest, the samples were centrifuged for 1 min at 13.000 rpm. After centrifu-
gation 50 µl of the supernatant, containing the DNA, were pipetted and put into a clean
tube.
PCR The polymerase chain reaction (PCR) is a technique to amplify a particular DNA
sequence. With this technique we could amplify a DNA sequence identifying either the
wild type gene or SMA variant. The method relies on thermal cycling, consisting of cycles
of repeated heating and cooling of the reaction for DNA melting and enzymatic replication
of the DNA. During the first step the DNA physically separate into two strands through a
high temperature around 90 ◦C. At a lower temperature, around 50 ◦C, the specific primers
can complementarily bind to the DNA. Starting from the primer, at a temperature around
65 ◦C, each strand is then used as the template in DNA synthesis by the heat stable DNA
polymerase (Taq Polymerase) to selectively amplify the target DNA. Building blocks for
the synthesis are the desoxyribonucleoside triphosphates (dNTPs). Repeating this cycle,
in our case 35 times, leads to an exponential amplification of the target DNA. The protocol
we used is based on a single tube reaction with 3 primers, two located in the WT gene
(A2F and A2R) region and one in the neomycin cassette present in KO mice.
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PRIMER MER Sequence 5’-3’
NeoB 21 GCA GCT GTG CTC GAC GTT GTC
A2R 25 CCT TAA AGG AAG CCA CAG CTT TAT C
A2F 21 GCT CTT GGC AAC CCT ACT GTC
Table 3: Primer Sequences
The reaction was done with the following components:
• 9.3 µl MQ water
• 4 µl MgCl2 (25mM)
• 2.5 µl buffer 10X (Biotools)
• 0.5 µl dNTPs 25mM (Invitrogene)
• 0.5 µl Neo B primer 10 µM (Sigma)
• 0.5 µl A2R primer 10 µM (Sigma)
• 0.5 µl A2F primer 10 µM (Sigma)
• 0.2 µl Taq 5U/ µl (Biotools)
• 1 µl DNA
Using the following PCR program: (1) 95 ◦C / 4 min, (2) 95 ◦C/ 1:30 min, (3) 62 ◦C /
1:30 min, (4) 72 ◦C / 1:30 min; 35 x steps 2 to 4, (5) 72 ◦ C / 4 min, (6) 4 ◦C / 1 h.
Electrophoresis
The amplified target DNA could be detected by gel electrophoresis, showing two dif-
ferent bands, one at 900 base pairs (bp) corresponding to the KO and another at 600 bp
corresponding to the WT gene. Both bands were amplified in heterozygous mice whereas
in homozygote mice only one band was detectable (Fig.8)
Figure 8: Electrophoresis showing null (-/-), heterozygous (+/-) and WT (+/+) genotypes with 900
bp corresponding to absence of the gene and 600 bp to the presence of the gene.
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2.2.2 Muscle Dissection
Mice were sacrificed by means of CO2 and immediately exsanguinated.
Transversus Abdominis (TVA)
The TVA is the inner muscle of the abdominal wall. For an optimal penetration during
immunochemistry all tissues above the TVA need to be removed carefully (Figure 9). As a
first step the mouse was positioned in dorsal decubitus and the abdominal skin was opened
through a midline incision and pulled to the sides. Second, the whole left hemi-abdominal
muscle wall, up to the sternum, was cut out and pinned to the bottom of a 2 ml chamber,
over a bed of cured silicone rubber (Sylgard, Dow Corning). Third, the Obliquus Externus
muscle and the fat tissue were removed carefully to obtain a free area of intact TVA muscle
fibers with their corresponding nerve branches.
Figure 9: Abdominal muscle wall from mice. In red Transverus Abdominus Muscle (TVA) used for
experiments ( self-made drawing).
Levator Auris Longus (LAL)
The LAL is located directly under the neck skin reaching from the cranial midline
towards the ears (Fig. 10). For the dissection, the hair was removed by shaving the area
between the left ear and the cranial midline. Second, the left neck muscle block with skin
was removed and pinned upside down to the bottom of a 2 ml chamber. Before removing
several other muscles (M.Splenius Capitis, M. Capitis Post Mayor, M. Cervicoscularis)
located over the LAL, the skin underneath was pulled to the side. Finally, the LAL was
cleaned from fat and connective tissue. Figure 10 shows the LAL with the two constituent
muscle bands (rostral and caudal).
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Figure 10: The Levator Auris Longus muscle LAL with two constituent muscle bands (rostral and
caudal) reaching from the cranial midline towards the ears (Taken from (Greene 1935), p. 130).
2.2.3 Immunocytochemistry and Toxin-Conjugated Labeling
Visualization of the different investigation targets
Postsynaptic side.The endplates were labeled with α-Bungarotoxin (α-BTX), a snake
toxin that binds to the muscle-type nicotinic acetylcholine receptor (nAChR). α-BTX was
conjugated to either rhodamine or Alexa Fluor 647.
Synaptic Vesicles were marked by using a primary antibody, anti-VAChT, against
the vesicular acetylcholine transporter. This primary antibody was visualized using a
secondary antibody containing a fluorescent dye. The vesicular acetylcholine transporter
VAChT is an integral membrane protein with 12 putative trans-membrane domains. VAChT
translocates acetylcholine from the cytoplasm into synaptic vesicles, where it stays until
release.
A second type of vesicle staining was done using a primary antibody against the synaptic
vesicular transmembrane protein (SV2). This primary antibody was again visualized using
a secondary antibody containing a fluorescent dye.
Mitochondria were labeled with Mito Tracker, a fluorescent dye containing a mildly
thiol-reactive chlormethyl moiety. This cell-permeant probe is oxidized when it enters an
actively respiring cell. Depending on the mitochondrial membrane potential Mito Tracker
diffuses passively across the membrane and accumulates in active mitochondria (Poot et al
1996). Specific staining of mitochondria depends critically on the viability of the prepa-
ration. Therefore, the dissection was done as quikly as possible with a minimun of cell
damage. Actin was labeled with phalloidin, a high-affinity probe for filamentous-actin
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(F-actin). The toxin phalloidin is extracted from a mushroom, amanita phalloides and
conjugated to a bright, far-red-fluorescent dye, Alexa Fluor 647.
The protocols
The different protocols differ only slightly from each other nevertheless they are de-
scribed completely to facilitate replication of the experiment.
Synaptic Vesicles and mitochondria staining
The muscles were dissected in hepes solution at pH between 7.35 and 7.4 (see sec-
tion 2.3.4.3. Solutions and Buffers), followed by 40 minutes incubation with 400 nM Mito
Tracker diluted in hepes solution. After washing with hepes solution, the preparations
were fixed in 4 % paraformaldehyde, washed with PBS and incubated at 4 ◦C over night.
Subsequently they were incubated with glycine 0.1 M in PBS for 30 min at room tempera-
ture to bind and removes aldehydes left over from the fixation step. Subsequently muscles
were permeabilized with 1% Triton X-100 in PBS. Unspecific binding sites were blocked
by incubation with 5% BSA in PBS-T for 3 hours, followed by incubation with primary
antibody (anti-VAChT) 1:500 (2.5% BSA in PBS-T 1%) for 30 minutes at room tempera-
ture. Muscles were stored at 4 ◦C over night. The next day they were incubated at room
temperature for 30 min; they were washed using 0.05 % Triton in PBS, then incubated with
the secondary antibody (goat anti-rabbit Alexa 488 diluted 1:500) and the postsynaptic
dye (1.25 µl/ml BTX Alexa Fluor 647 ) in 5% BSA in PBS-T 0.05%. After washing with
PBS-T 0,05% the muscles were finally mounted under the stereoscopic microscope with
slowfade medium.
Synaptic Vesicles staining with SV2 and AChT labeling
The muscles were dissected in hepes solution (see section solutions and buffers). Sub-
sequently fixed in 4% paraformaldehyde and washed with PBS, followed by 30 min incu-
bation with glycine 0, 1 M in PBS at room temperature and permeabilization with 1%
Triton X-100 in PBS. Unspecific binding sites were blocked by incubation with 5 % BSA
in PBS-T for 2 hours at room temperature and then at 4 ◦C over night. After incubation
at room temperature for 30 min, the preparations were incubated with primary antibod-
ies (anti-SV2) and (anti- VAChT) 1: 500 (2.5% BSA in PBS-T 1%) for 2 hours at room
temperature, followed by washing with PBS-T 1%. Together with the postsynaptic dye (1
µl /ml BTX Rhodamine), they were incubated for 1 hour with secondary antibodies goat
anti-rabbit Alexa 488 and goat anti-mouse Alexa 647 1:500 diluted in 5% BSA in PBS-T
0.05 %. Before mounting the preparation under the stereoscopic microscope they were
washed with PBS-T 0, 05 %.
Synaptic Vesicles and Actin staining
The muscles were dissected in Hepes solution (see section 2.3.4.3. solutions and buffers)
and then fixed in 4 % paraformaldehyde, washed with PBS and set at 4 ◦C over night.
Subsequently they were incubated with glycine 0, 1 M in PBS at room temperature, then
permeabilized with 1 % Triton X-100 in PBS. Unspecific binding sites were blocked by
incubation with 5% BSA in PBS-T for 3 hours. Followed by incubation with primary
antibody (anti-VAChT) 1:500 (2,5% BSA in PBS-T 1%) for 30 minutes at room temper-
ature. They were stored at 4 ◦C over night. The next day they were incubated at room
temperature for 30 min; they were washed using 0.05% Triton in PBS, then incubated with
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the secondary antibody (goat anti-rabbit Alexa 488 diluted 1:500), the actin dye (25 µl/ml
Alexa fluors 647 phalloidin) and the postsynaptic dye (1.25 µl/ml BTX-Rhodamine red)
in 5% BSA in PBS-T 0,05 %. After washing with PBS-T 0,05 % the muscles were finally
mounted under the stereoscopic microscope with slowfade medium.
2.2.4 Confocal Microscopy
Muscles were imaged with an upright Olympus FV1000 confocal laser scanning microscope,
equipped with three excitation laser lines (488, 561 and 633 nm). A 10x objective was used
for coarse localization of nerve terminals within the preparation. Images were taken using
a 63x oil-immersion objective with a numerical aperture of 1.4. Fluorescence emission was
detected sequentially by selecting the appropriate filter settings, as given in the Table 4.
Label Exc Max (nm) Em Max nm
α-Bungarotoxin Alexa Fluor 647 650 668
α-Bungarotoxin Rhodamine 552 579
Secondary Antibody Alexa488 495 519
Alexa flour 647 phalloidin 650 668
Mito Tracker Orange CMX Ros 554 576
Table 4: Filter settings for detection of specific fluorescent labels.
2.2.5 Image Analysis with ImageJ
Transferring the image from the Olympus Fluoview program to the Image J
program
The Olympus Fluoviewprogram was used to acquire the emission of each dye, for example
BTX far red, Mito Tracker and Alexa Flour 488 in individual channels in three (X-Y-Z)
dimensions. The Z dimension was represented as a series of slices, showing the emission
from different depth levels at intervals of 0.5 µm. The images were imported from the
Olympus Fluoview program to the Image J program in a RGB red green and blue color
format as a sequence containing images at about 8 z-positions per fluorescence channel.
The image sequence from different depth levels of each channel was transformed to a
Z-projection, when required. After setting the scale in µm corresponding to one pixel,
Z-projections were used for imaging analysis. In some cases single slices were used for
analysis, if mentioned in the text.
Measuring the postsynaptic area
The Z-projection showing the postsynaptic area labeled by BTX -Rhodamine or BTX-Far
red, was converted from RGB color image to an 8 bit grayscale image. The image was
segmented into regions of interest and background by setting interactively lower and upper
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threshold values. The area of a selected region was then measured in square micrometers
using image J routines.
Measuring the area of synaptic vesicle clusters
In order to measure the synaptic vesicle clusters, lower and upper threshold values were
set as for the postsynaptic side, with the difference that the areas of interest were analyzed
in “particles analyzing mode” by manually setting the threshold until edges of each vesicle
cluster were defined. Then the individual areas of each cluster were measured.
Measuring the area of the mitochondria clusters
In contrast to synaptic vesicles, mitochondria are present in all cells. To measure only
the mitochondria inside the terminal we used the postsynaptic area as a mask and cleared
all signals outside this region. The mitochondria inside the synaptic terminal were then
measured in “particles analyzing mode”, similar to the analysis of vesicle clusters.
Actin measurements
In transverse single confocal slices the diameters of F-actin rings surrounding SVs could be
estimated from their respective line-intensity profiles. From maximum projected confocal
images actin areas were determined automatically, by defining masks based on brightness
thresholding. To measure only the actin inside the terminal we used the postsynaptic area
as a mask and cleared outside signals before measuring actin.
Quantification of the nearest-neighbor distances between SV clusters and mi-
tochondria spots
Nearest-neighbor distances between mitochondria and SV clusters were determined by
fitting each of the red and green spots to a 2D gaussian distribution, and using the distances
between the peaks (x,y) of the distributions.
2.2.6 Statistics
Unless otherwise stated all values indicate mean ± standard error of the mean (sem) and
numbers (n) refer to the number of terminals. Differences between groups were tested
using the t-test (2 tailed).
Chapter 3
Results
The results of this work have been incorporate into our publication “SMN Requirement for
Synaptic Vesicle, Active Zone and Microtubule Postnatatal Organisation in Motor Nerve
Terminals” (Torres-Benito et al 2011).
3.1 Synaptic Vesicles
3.1.1 Deficits in Synaptic Vesicle Maturation
Synaptic Vesicles (SV) together with mitochondria are the main organelles in the nerve
terminal. A disturbed distribution or reduced amount of SVs could provide an explanation
for the observed 55% decrease of evoked neurotransmitter release in TVA muscle of SMA
mice (Ruiz et al 2010).
We used an antibody against the vesicular ACh transporter (VAChT) in combination
with a secondary antibody, conjugated with a green fluorophore to explore the SVs spatial
organization. In particular the total area of the terminal covered by SVs was determined.
To better localize the NMJ we labeled, like in all the following experiments, also the post-
synaptic side with α-Bungarotoxin (α-BTX), which binds to the nicotinic acetylcholine
receptor (nAChR), in this case conjugated with rhodamine.
Spinal Muscular Atrophy progresses during development. To get insight into the presy-
naptic maturation process, we examined synaptic structures in mice at postnatal day seven
(P7) and 14 (P14). We used TVA muscle, one of the most affected ones in this disease
(Murray et al 2008) (Ruiz et al 2010).
The confocal images show that SVs are organized in clusters (Fig. 11 for P7 and Fig. 12
for P14). In wild-type (WT) mice, at the beginning of the NMJ postnatal maturation
period (first week of life), SV clusters were observed to be small (Fig. 11A), but by the
second week, as WT NMJs matured, SVs covered larger areas of the terminal (Fig. 12A).
In SMN deficient terminals, however, SV clusters remained small (compare Fig. 12A, upper
and lower panels).
Also, at the postsynaptic side, images taken at P14 showed signs of immaturity.
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Figure 11: Representative en face views of NMJs from the TVA muscle at P7 stained
with BTX-Rho (red), which binds specifically to postsynaptic AChRs, and anti-
VAChT (green), which labels synaptic vesicles. Images are Z-stack projections. A. Terminals
of WT (upper panels) and SMN∆7 mice (lower panels) respectively, at P7. Panels B; C & D show
mean values ( ±sem) of BTX area, total synaptic vesicle area and their ratio respectively both for
WT (white bars) and mutants (grey, filled bars). Scale bars: 10 µm *:P < 0.05; **:P < 0.005;
***:P < 0.0005.
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Figure 12: Representative en face views of NMJs from the TVA muscle at P14 stained
with BTX-Rho (red), which binds specifically to postsynaptic AChRs, and anti-
VAChT (green), which labels synaptic vesicles. A. Terminals of WT (upper panels) and
SMN∆7 mice (lower panels) respectively, at P14. Note the signs of immaturity in the SMN∆7
terminals: no clear folders or perforations at the postsynaptic side in SMN∆7 (left, lower panel)
compared to WT (left, upper panel). SVs at the presynaptic terminal remain small in SMN∆7 mice
(right, lower panel). B. Mean postsynaptic area in SMN∆7 (grey, filled bars) and in WT terminals
(white bars) are significantly different. C. The total area of vesicles stained with VAChT is smaller
in ∆7 mice than in WT motor terminals. D. The relative area covered by vesicles in relation to the
area covered by postsynaptic receptors is less than half in SMN∆7 terminals. Scale bars: 10 µm
*:P < 0.05; **:P < 0.005; ***:P < 0.0005.
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While in control littermates band structures were apparent, representing BTX, which
resides at the lips of infoldings, no such features were obvious in images from mutants
(compare Fig. 12A upper and lower panels). A quantitative analysis of the images is
shown in Figure 11B-D and 12B-D.
Measuring the area of the postsynaptic side (see methods) showed that NMJs are
smaller in mutants both at P7 and P14 (Fig. 11B & 12B, respectively). Therefore, the
areas covered by SVs were normalized to those of the postsynaptic terminal, in order
to compare the fractional area covered by SVs between mutants and control. The total
surface of the terminal covered by SVs was ∼30% smaller in SMN deficient terminals (n
= 37 NMJs from 3 mice) than in WTs (n = 38 NMJs from 3 mice) already at P7 (Fig.
11C & D P < 0.0001). At P14, this difference became even larger, near 50%, (Fig. 12C
& D; P < 0.0001; WT: n = 52; ∆7: n = 58 terminals). In addition, the size of SV
clusters was smaller in mutants than in WTs, both at P7 (∼30%; P = 0.02) and, much
more so, at P14 (75%; P < 0.0001). This analysis shows the phenomena of maturation
in a remarkable way: in littermate controls the clusters size increased and the number of
clusters diminished (see Table 5) from P7 to P14. In contrast, in mutants this process was
not observed, no change in cluster size, nor in the number of clusters per terminal took
place during the second week of life.
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3.1.2 VAChT and SV2 colocalize in SMA Motor Terminals
To test whether the clustering of SVs observed in the TVA muscle of SMA mutants with
anti-VAChT antibodies could also be seen with another vesicle marker, a double staining
of SVs using antibodies against VAChT, and the synaptic vesicle protein 2 (SV2) was
performed. The vesicular fluorescence patterns observed with anti-VAChT (red) were also
seen with anti-SV2 (green), both in WT (Fig. 13A), and in mutant terminals (Fig. 13B).
Quantitative analysis of the immunofluorescence signals indicated that the colocalization
indexes (see Methods) of these two markers were ∼0.9 in both types of mice. These data
corroborate the smaller size of the clusters in SMA mutant terminals, and rule out the







Figure 13: VAChT and SV2 colocalize in SMA synaptic vesicles. A & B. Examples of
WT and SMA ∆7 terminals at P14 from TVA muscles. Images are Z-stack projections. Scale bar: 5
µm.
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3.1.3 A reduced SV pool can coexist with a mature Postsynaptic
Terminal in LAL Muscle.
The data presented above show that SMA deficiency produces pre- and postsynaptic defects
in the TVA muscle, and raise the question of how much the pre- and the postsynaptic
phenotypes are interrelated in SMN deficient mice. Therefore, it was explored whether
the vesicle content was also anomalous in the LAL muscle of SMA mutants, a muscle, in
which postsynaptic terminals have been described to mature almost at the same pace as
in control mice Murray et al (2008). The analysis, as described for the TVA, therefore,
was repeated in the LAL.
Because previous work has identified a selective vulnerability of the nerve terminals in
the caudal band in comparison to the rostral band of the LAL muscle (Murray et al., 2008;
Ruiz et al., 2010), the size of the postsynaptic side and the organization of SVs at NMJs
in both bands was compared.
In the rostral band there was no significant difference in the size of the postsynaptic
side at P7 (Table 5), and P14 (Fig. 14 E and Table 5). Also in the caudal band there was
no difference in size of the postsynaptic side at P7 (Table 5). Only in the caudal band
at P14 the size of the postsynaptic side was ∼23% reduced in mutants (Fig. 14B). In
comparison: in TVA muscle at P14 the size of the postsynaptic side was ∼33% smaller in
mutant relative to WT.
At P7 in the rostral band, SV area and mean cluster area (Table 5) were not different
in WTs (n = 21 terminals) and mutants (n = 22 terminals), while both parameters were
significantly reduced in mutants at P14 (Table 5). More specifically, at P14 the mean SV
area was reduced ∼52% and mean size of SVs clusters was reduced ∼66% in mutant (Fig.
14F & G), (P = 0.0003 and P = 0.006, respectively). In the caudal part, however, both
parameters were already decreased at P7 in mutants. At P7 the SV area was ∼49% and
the SV cluster size was ∼57% smaller (Table 5). At P14 this difference even increased, the
SV area was ∼73% and the SVs cluster size ∼ 83% reduced (Fig.14C & D, respectively).
These results demonstrate that the observed abnormalities are not a property of the
TVA muscle alone. Moreover, they confirm the selective vulnerability of the caudal band
of the LAL muscle. The finding that the maturation of the postsynaptic end-plates takes
place normally while there are early presynaptic defects, shows that pre- and postsynaptic
defects can occur independently from each other.
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Figure 14: Synaptic vesicle reduction and anomalous distribution in SMA motor
terminals from LAL muscles despite mature postsynaptic side. A & B. Representative
images of pre- and postsynaptic characteristics of NMJs in the LAL muscles of WT (upper panels) and
SMN∆7 (lower panels) mice at P14. Postsynaptic terminals were labeled with BTX-Rho (red) and
presynaptic vesicles with antibodies against VAChT (green). Note the clustering of SVs despite the
mature appearance of the postsynaptic side in the SMN∆7 terminal. Scale bar: 5µm. B-G. Mean
postsynaptic area (B & E), SV area (C, F), and cluster area (D, G) in SMN∆7 and WT terminals,
from rostral (B-D) and caudal (E-G) divisions of the muscle at P14. Note that the area of vesicles
and the cluster sizes were significantly reduced at P14. However, in the caudal part SV deficiencies
in SMN∆7 terminals were evident since P7 (n = 16 WT terminals and n = 15 SMN∆7 terminals).
Scale bars: 10 µm *:P < 0.05; **:P < 0.005; ***:P < 0.0005 (modified from our publication









WT D7 WT D7 WT D7 WT D7
TVA
Mean 193,3 139,2 0,383 0,274 2,304 1,628 0,192 0,201
P7 sem 7,548 7,475 0,0133 0,0185 0,207 0,212 0,01 0,011
n 38 37 38 37 38 37 38 37
Mean 208,3 140,2 0,479 0,239 6,687 1,772 0,09697 0,19145
P14 sem 8,338 6,77 0,019 0,014 0,632 0,1598 0,0055 0,009
n 52 58 52 58 65 68 52 58
LAL Rostral
Mean 185,2 181,1 0,28 0,2684 1,627 1,375
P7 sem 11,452 13,678 0,0262 0,023 0,311 0,2045
n 21 22 21 22 21 22
Mean 213,7 186,1 0,47016 0,2612 3,411 1,1525
P14 sem 15,7863 11,037 0,02615 0,0176 0,55 0,105
n 7 12 7 12 7 12
LAL Caudal
Mean 173,2 168,4 0,367 0,193 2,0975 0,9
P7 sem 9,391 12,058 0,0396 0,019 0,338 0,1
n 16 14 16 14 16 14
Mean 250,1 191,8 0,574 0,197 5,9863 0,999
P14 sem 18,5996 16,05 0,0393 0,024 0,717 0,0861
n 11 15 11 15 11 15
Table 5: Summary of synaptic vesicle and postsynaptic side properties in TVA and
LAL muscle. Comparison between WT (wild type) and D7 (SMA mutant) in TVA (Transversus
Abdomnis Muscle) and LAL (Levator Auris Longus muscle) at P7 (seven days old mice) and P14
(fourteen days old mice), regarding BTX Area (µm2) (area of postsynaptic side), SV Area/BTX Area
(Area of the synaptic vesicles divided by area of postsynaptic side), SV cluster size (µm2) (mean size
of one single vesicle synaptic vesicle cluster) and number of clusters/BTX Area. Data in mean, sem
(standard error of the mean) and n (number of observations).
3.2 Mitochondria
3.2.1 Mitochondria Clusters are smaller in SMA Motor Termi-
nals
Mitochondria provide ATP for synaptic transmission, ion pumps, and the assembly of the
actin cytoskeleton involved in the clustering of SVs and mitochondria themselves (Hirokawa
and Takeda 1998; Langford 2002). Furthermore they regulate intraterminal Ca2+ levels,










WT D7 WT D7 WT D7
TVA
mean 22,9 23 0,29 0,19 1,72 0,89
P14 sem 2,1 3,1 0,03 0,02 0,36 0,1
n 18 19 22 20 360 214
Table 6: Summary of mitochondria properties in TVA muscle. Comparison between WT
(wild type) and D7 (SMA mutant) in TVA (Transversus Abdominus Muscle) at P14 (fourteen days
old mice), regarding Number of Mito Tracker spots per terminal. Total area of Mito Tracker Spots
/BTX Area (µm2) and Mito Tracker spot size (µm2). Data in mean, sem (standard error of the
mean) and n (number of observations).
and Barrett 2000). Therefore, a reduction in the number of mitochondria, alterations in
their spatial distribution, or impairment of their functional capacities may decrease their
Ca2+ buffering capability and produce toxic Ca2+ overloads. To assess whether the spatial
distribution of mitochondria or their density was altered in SMN deficient terminals, the
TVA muscle was incubated with Mito Tracker (400 nM), a cell-permeant probe that is
sequestered by intact mitochondria and retained during cell fixation (Poot et al 1996).
Figure 16 A-D (central panels) shows representative examples of the distribution of
Mito Tracker labeled mitochondria in motor terminals at P14. The total area stained
by Mito Tracker per terminal was about half in mutants (19.4 ± 2.7 µm2; n = 20) as
compared to WT terminals (38.8 ± 4.9 µm2; n = 22; P = 0.002). Normalization of these
areas to postsynaptic surfaces also gave significantly smaller values in mutants (WT: 0.29
± 0.03; mutant: 0.19 ± 0.02; P = 0.01) (Figure 15A). This difference was mainly due to
the smaller size of the Mito Tracker spots (WT: 1.72 ± 0.36 µm2, n = 360 spots; mutant:
0.89 ± 0.1 µm2, n = 214 spots. P = 0.03) in mutants (Figure 15 C). Quantification of
the number of Mito Tracker microregions per terminal showed no significant differences
between WT and mutants (WT: 22.9± 2.1 spots/terminal, n= 18 terminals; mutant 23.5
± 3.1, n = 19 terminals) (P = 0.9) (Figure 15C).
These properties of mitochondria in TVA muscle of SMA mice compared to wild type
are also shown in Table 6.
3.2.2 Co-clustering of Mitochondria and SV clusters
Next, we explored the spatial relationship between Mito Tracker spots and SV clusters. In
most cases, as in the illustrated examples, mitochondria (red) appeared near SV clusters
(green) in both WT (Fig. 16A & B) and mutant terminals (Fig. 16C & D). Moreover, in
many cases a core of mitochondria was clearly surrounded by a SV rim (Fig. 16A-D, right
panels), reminiscent of the donut-like structures described in the calyx of Held, Wimmer
et al (2006) and Perkins et al (2010).
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Figure 15: A-D. Staining of mitochondria with Mito Tracker in WT (wild type) and
D7 (mutant mice) in TVA muscle at P14. A. The total area stained by Mito Tracker
normalized to the postsynaptic surfaces was significantly reduced in mutant. B. Quantification of
numbers of Mito Tracker spots per terminal showed no significant difference between WT and mutant.
C. The size of Mito Tracker spots is smaller in mutant. D. Relationship between mean areas covered
by SV and mitochondria in WT (blue) and SMA ∆7 (red) terminals. *: P < 0.05.
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To quantify this observation we measured the nearest-neighbor distances between SV
clusters and mitochondria spots. Nearest-neighbor distances were determined by fitting
each of the red and green spots to a 2D Gaussian distribution, and using the peak (x,y) of
each distribution. The results in nine mutant terminals (202 measurements) and 13 WT
terminals (282 measurements), showed that in mutants SV and mitochondria were closely
associated, as in controls (Fig. 16 E). Even more, the percent of red-green spots nearest
distances within 1 µm were larger in mutants (41%) than in WT (31%) (P = 0.0006), as
expected for the smaller sizes of SV and mitochondria cluster in mutants. Taken together,
these results show that in nerve terminals mitochondria and SVs clusters are localized in
pairs. This aspect of the spatial organization is not altered in mutant terminals, whereas
the fractional area covered by mitochondria is reduced.
3.3 F-actin
3.3.1 F-actin forms ring-like Structures around SV Clusters
Filamentous actin (F-actin) is a prominent cytoskeletal element in nerve terminals. The
F-actin-based network may participate in creating a scaffold for SV clustering, and/or in
supporting ordered vesicle mobility (Hirokawa et al 1989). In addition, it has been sug-
gested that F-actin anchors synaptic vesicles to AZs by a labile link formed with synapsin,
a vesicle protein De Camilli et al (1990) and Greengard et al (1993).
SMN deficiency produces defects in β-actin mRNA axonal transport, and a decrease
in actin protein content in growth cones of motoneurons in culture (Rossoll et al 2003).
We explored F-actin content and distribution in presynaptic TVA motor terminals of SMA
mutant mice. F-actin was revealed by binding to fluorescent Phalloidin-Alexa 647, which
binds to all isoforms of F-actin but not to monomeric actin (Wulf et al 1979). In addition,
to gain insight into the role of F-actin in the organization of SV, the distributions of F-actin
relative to SV were also examined.
F-actin was localized in the sub-plasmalemmal region, extending into the cytoplasm
and forming a thin network. Figure 17A shows a WT terminal with F-actin labeled with
phalloidin (upper panel), SV labeled with VAChT antibodies (green), and postsynaptic
receptors labeled with BTX-Rho (red, lower panel). In Figure 17B a typical terminal from
a mutant mouse is shown (left panel, phalloidin image; central panel, anti-VAChT and
BTX-Rho merged). In some cases, F-actin was also clearly visualized in the axon (Fig.
17B, arrow in right panel). In WT and mutant mice, F-actin filaments run parallel to the
major axis of the terminal and SV clusters are positioned along them.
The association between SV clusters and actin could be better visualized in transverse
single confocal slices. Figure 17C (WT) and 17D (mutant) present two representative
examples showing SV clusters surrounded by F-actin, forming ring-like structures, similar
to actin rings described in the lamprey reticulospinal giant synapse (Shupliakov et al 2002).
Interestingly, the diameter of F-actin rings surrounding SV were apparently smaller in
mutant than in WT terminals, as could be appreciated by their respective line intensity
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Figure 16: Mitochondrial density in SMA presynaptic terminals is reduced. Data are
from the TVA muscle (P14).A - D.The upper panels (A & C) show Z-stack projections while the lower
panels (B & D) show single confocal sections. The staining from left to right are: BTX-A647 (grey),
SVs (green), Mito Tracker (red), merge of SV and mitochondria. E. Nearest neighbor distributions
of SV clusters and mitochondrial regions (calculated from their respective center of mass), in WT
and mutants terminals. Scale bars A-D: 5 µm; insets: 600 nm (from our publication Torres-Benito L,
Neher MF, Cano R, Ruiz R, Tabares L., 2011)
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profiles across SVs and phalloidin loops (Fig. 17E). However, these structures were not
visualized frequently enough for statistical analysis. Thus, the percentage of the terminal
area covered by phalloidin, normalized to the postsynaptic area, was quantified (Fig. 17F).
In WT mice, although the area of the terminal covered by phalloidin was apparently larger
than in mutants (WT: 41 ± 9%, n = 6 terminals; mutants: 34 ± 4%, n = 6 terminals),
this difference did not reached statistical significance (P = 0.5).
Taken together, these results show that, although a slight reduction of the F-actin
based network is difficult to quantify, F-actin is still present in high amounts in the mutant
and, similarly to the wild type case, closely associated with SVs in the form of ring-like
structures.
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Figure 17: F-actin and SV are closely associated in SMA motor terminals. Data are
from the TVA muscle (P14). A - B. Representative examples of the distribution of F-actin (gray)
in a WT (A) and a mutant (B) terminal. The same terminals are also shown stained for SV (green)
and postsynaptic receptors (red). Arrow in the right panel of B points to actin in the axon. C - D.
Phalloidin (blue), SV (green), and AChRs stained with BTX-Rho (red), showing the organization of
actin around SV clusters in a WT and a mutant (D) terminal. E. Intensity profiles across actin loops
and SV clusters showing the reduced diameter and thickness of the loop in mutants. F. Phalloidin
areas in WT and mutant terminals were not significantly different (P < 0.05). Scale bars: A & B:




Spinal muscular atrophy (SMA), a frequent neurodegenerative disease, is caused by reduced
levels of functional SMN. SMN is a ubiquitously expressed protein, however reduced levels
of SMN predominantly affect motor neurons and muscles.
The following studies revealed important insights to understand this phenomena:
• In search of a neuron-specific function of SMN it was shown that SMN interacts with
β-actin mRNA and mediates its transport along the axon (Rossoll et al 2003).
• Functional studies at neuromuscular junctions (NMJ) showed that the evoked neu-
rotransmitter release was decreased by approximately 55% in most affected muscles,
indicating a decreased number of fused vesicles, while asynchronous release is in-
creased by ∼300% due to an anomalous accumulation of intraterminal bulk Ca2+
in SMA mice (Ruiz et al 2010). A possible explanation of this augmentation is a
decreased Ca2+ reuptake by mitochondria during trains of action potential.
Starting from these results, here, we undertook a manifold morphological study regarding
synaptic vesicles (SVs), mitochondria and actin at the NMJ of SMN deficient mice in order
to better understand the disturbed neurotransmission mentioned above and to learn more
about actin as a possible key player in SMA pathogenesis.
4.1 Synaptic Vesicle Clusters remain small in SMA
mice during Maturation
Our fluorescence microscopy images using an antibody against the vesicular acetylcholine
transporter (vAChT) show clearly, that synaptic vesicles are organized in clusters in the
presynaptic motor terminal.
We demonstrated that in wild type muscles, as a pattern of maturation, the SV clusters
increased highly in size while their number diminished between P7 and P14. In mutant
mice, however, the clusters remained small and the number of clusters did not change.
Hence at P7 the total surface of the terminal covered by SV and the average size of any
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given cluster was equally reduced by ∼30% in mutant mice. At P14 these differences
became even larger, while in littermate controls the cluster size increased, and the number
of clusters diminished. In mutants no change in cluster size, nor in the number of clusters
per terminal, took place. In numbers, at P14 the total surface of the terminal covered by
SV was near 50%, and the size of SVclusters was ∼ 75 % reduced in mutant mice. This is
in agreement with an electron microscopy study of NMJ in tibialis anterior muscle at P13
demonstrating that individual synaptic vesicles within the presynaptic terminal had normal
diameter and morphology, but their overall density within the presynaptic terminal area
was reduced by 56% (Kong et al 2009). Accordingly, another ultrastructal study showed
a decrease in SV density in SMA mice (Lee et al 2011). In contrast in diaphragm at P14
no significant difference in vesicle number was found (Kariya et al 2009). The finding
that the size of SV clusters increases during maturation leads to the question whether
single vesicles increase in size, their density within clusters decreases, or the number of
vesicles increases. The amplitude of spontaneous miniature endplate currents (mEPC),
representing the muscle response to neurotransmitter release from a single vesicle, was
found to be normal in SMA mice. This indicates that the size of single vesicles is normal
and suggests that a reduced number of vesicles or increased vesicle density leads to the
smaller SV cluster size (Kong et al 2009).
However our images provide only information about the area of maximum projections
of SV clusters. Also, light-microscopic images of clusters do not provide numbers on
the density of vesicles within clusters. Disregarding such problems and assuming tightest
possible vesicle packing a very rough estimation on how many SV might form one SV
cluster can be obtained by dividing the volume of a sphere with the diameter of one SV
cluster (2.6 µm, in wild type TVA at P14) by the volume of one vesicle (0.0395 µm in
diameter). Doing so we arrive at a very high number - 285000. This is orders of magnitude
larger than estimates from electron microscopic studies on the number of vesicles per active
zone for mammalian glutamatergic synapses (200 to 250). It is, however, compatible with
estimates in ribbon synapses (10000 to 13000), if a volume fraction of about 0.05 is assumed
(see (Fernndez-Alfonso and Ryan 2006), 2006, for a review on vesicle numbers). Under the
same assumption the total vesicle pool in frog neuromuscular junction contains ∼ 500,000
vesicles ((Ceccarelli et al 1973); (Heuser and Reese 1973); (Molgo and Pecot-Dechavassine
1988); (Rizzoli and Betz 2005)). We could show that the area of the cluster size increases
three times from P7 to P14 in wild type TVA, which would mean a 5.2 times increase in
the number of vesicles at constant packing density. In contrast in SMA mice the cluster
size remains almost the same from P7 to P14.
However, repeating similar experiments using a fluorescent microscope with a resolu-
tion high enough to identify single vesicles or else an electronmicroscopic analysis would
certainly be an interesting extension of our study.
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4.2 Selective Vulnerability of Motor Neurons inner-
vating the Caudal Band of Levator Auris Longus
muscle (LAL) despite only modest Abnormalities
at the Postsynaptic Side
To study SV in a different anatomical region we perfomed the same analysis we did in TVA
muscle in LAL muscle. In LAL muscle we showed that SV pathology is more severe in the
caudal band than in the rostral band. There was no differences between mutant and wild
type regarding the SV area and mean size of SV clusters in the rostral band at P7, while
both parameters were significantly reduced in mutants at P14. On the contrary, in the
caudal band both parameters were already decreased at P7. The reduction in the caudal
band of the area covered by SV and mean size of SV clusters was even more profound than
in TVA muscle.
These results, identifying the caudal band to be more affected in the disease than the
rostral band, is in agreement with a study showing that presynaptic nerve terminal loss
was widespread in the caudal band but almost absent in the rostral band (Murray et al
2008). After excluding other possibilities, it is likely that this selective vulnerability in the
caudal band is due to the Fast Synapsing (FaSyn) characteristic, while in rostral band the
Delayed Synapsing (DeSyn) characteristic is dominant (Murray et al 2008). However this
does not demonstrate a direct link between FaSyn characteristics and selective vulnerability
since genetic tools to experimentally manipulate FaSyn and DeSyn characterestics are
not available yet. To get more insight into the question what makes some muscles more
vulnerable than others, it would be of interest to proof whether also the TVA belongs to
the class of Fast Synapsing muscles.
The comparison of postsynaptic sizes revealed that the reduction at the postsynaptic
side is much more profound in TVA than in LAL. This is in agreement with a study show-
ing that the reduction of muscle fiber diameter and postsynaptic endplate shrinkage was
profound in TVA, but only modest in LAL (Murray et al 2008). For a better understand-
ing of the disease it is essential to define whether postsynaptic pathology at the NMJ is a
consequence of pathology of the nerve or occurs independently from presynaptic pathology.
In case postsynaptic pathology is a consequence of presynaptic pathology we would
expect that abnormalities at the postsynaptic side are correlated to pre- synaptic abnor-
malities. Here we could show, however, that in the caudal band of LAL a marked reduction
of the pool size of SV is present in the presynapse, despite only modest abnormalities of
its postsynaptic side. This finding suggests that postsynaptic pathology occurs largely in-
dependently from presynaptic pathology. According to that it was shown that presynaptic
nerve terminal loss can occur independently from postsynaptic endplate shrinkage at the
neuromuscular junction (Murray et al 2008). Thus, it is unlikely that postsynaptic pathol-
ogy is a plain consequence of disturbed neuronal signaling. One possible explanation for
this is that perturbed SMN gene activity may be required in both neuronal and muscle
tissue to result in the pathological phenotype (Chan et al 2003). Neuron-specific functions
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of SMN are well documented with SMN being shown to be important for events including
axon outgrowth, pathfinding, and neuronal maintenance ((McWhorter et al 2003); (Rossoll
et al 2003); (Ferri et al 2004)).
The muscle-specific role is still not comprehensively explored. Deletion of SMN exon
7 in mouse muscle is known to cause severe muscular dystrophy (Cifuentes-Diaz et al
2001) and a recent study, utilizing a drosophila model of SMA, has identified an important
role for the SMN protein in specifying form and function of muscle sarcomeres (Rajendra
et al 2007). Accordingly, a study in SMA mice shows that the molecular profile of muscle
pathology in SMA, with an upregulation of voltage-dependent anion-selective protein 2
(Vdac2) and downregulation of parvalbumin, was distinct from that of denervated muscle.
This adds further to the hypothesis that SMN-induced changes in muscle cannot solely be
attributed to motor neuron degeneration (Mutsaers et al 2011).
One possibility to better clarify to what extend pre- and postpathology are interre-
lated would be to repeat the current set of experiments in a mouse model, in which SMN
expression has been reduced specifically either in muscle or nerve tissue.
4.3 Mitochondrial Clusters are smaller in SMA Mo-
tor Terminals
We could show that mitochondria are organized in clusters and that the number of clusters
per terminal is the same in mutant and wild type at P14. However the mean size of clusters
was reduced by about one half in mutants and accordingly the total area of mitochondrial
clusters per terminal was ∼ 50% reduced in mutants.
Little is known about the role of mitochondria in SMA pathogenesis. In one electron
microscopy (EM) study on P14 SMA mice presynaptic mitochondria in diaphragmatic
muscle are decreased in size but not in numbers (Kariya et al. 2008). In contrast, another
electron microscopy study on P14 SMA mice showed in Tibiales Anterior muscle a reduced
density of mitochondria, while mitochondrial morphology was normal (Kong et al 2009).
Therefore it remains unclear, whether our finding of a reduced size of mitochondrial clusters
is due to smaller mitochondria or reduced number of mitochondria in SMA mice. The
staining of mitochondria with the fluorescent dye Mito Tracker is problematic: the uptake
of Mito Tracker into mitochondria depends on the negative resting membrane potential.
Therefore mitochondria had to be in a fairly viable condition to achieve specific staining.
We had to exclude many preparations from further analysis because Mito Tracker did not
enter sufficiently into the mitochondria.
On the other hand, although the Mito Tracker signal does not provide information
about the functionality of mitochondria in all aspects, one advantage of this probe is that
it does confirm that mitochondria are still active to maintain a negative resting membrane
potential. Hence we could compare the amount of active mitochondria in mutant and wild
type.
Mitochondrial dysfunction is known to play a central role in the pathogenesis of ma-
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jor neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s disease, and
amytrophic lateral sclerosis. This is not surprising regarding the two faces of mitochon-
dria. Besides being sources of ATP, mitochondria are also the main producers of reactive
oxygen species (ROS). If ROS levels overwhelm the defense mechanisms of the cells, ox-
idative damage of proteins, lipids, and DNA occurs ((Valko et al 2007); (Carvalho et al
2009)). Another consequence of mitochondrial impairment is the release of pro-apoptotic
factors and a reduced Ca2+ buffering capacity. At the presynaptic side rapid recovery of
Ca2+ transients is essential for nerve signaling. Interestingly at NMJ of SMA mice the
asynchronous neurotransmitter release (see introduction) was found to be increased by ∼
300 % indicating an anomalous augmentation of intraterminal bulk Ca2+ during repetitive
stimulation (Ruiz et al 2010).
Permanent Ca2+ overload is toxic for the cell as a result of several cross-amplifying cas-
cades, which will be briefly mentioned here. First, Ca2+ activates the cysteine proteases of
the calpain and caspase families, that degrade a variety of substrates and trigger apoptotic
cascades ((Chan and Mattson 1999); (Nixon 2003)). Second, Ca2+ induces oxidative stress,
among others through the activation of oxygenases (Lipton, 1993; Mattson and Pedersen,
1998). Third, Ca2+ triggers apoptosis through activation of pro-apototic proteins such as
Bax, Par-4, and p53 leading to mitochondrial membrane permeability changes, release of
cytochrome C, and caspase activation ((Duan and Cooke 1999); (Dargusch et al 2001);
(Culmsee and Mattson 2005)).
Regarding the finding of Ca2+ accumulation at the presynaptic side of SMA mice and
the obliterative effect of Ca2+ overload on the cell in general, it is obvious that answering
the question how Ca2+ accumulation comes about in SMA might provide an important
step towards a possible therapy of the disease. At the presynaptic side, the influx of Ca2+
through voltage-dependent and ligand-gated channels in the plasma is a critical signal for
the release of neurotransmitters ((Yuste et al 2000); (Burnashev and Rozov 2005)).
Normally, Ca2+ is then removed from the cytoplasm by plasma membrane Na+/Ca2+
exchanger, plasma membrane and ER Ca2+-ATPase, as well as Ca2+-binding proteins such
as calbindin and parvalbumin (Hof et al 1999). Moreover, Ca2+ can be transported into
and released from mitochondria ((Werth et al 1994); (Duchen 2000); (Nicholls 2003)). This
raises the question to what extend mitochondrial dysfunction contributes to the altered
Ca2+ homeostasis in SMA. Here we could show that the amount of active mitochondria
is about half in mutants. Further work is required to find out whether the remaining
mitochondria still function in their role to regulate intraterminal Ca2+ levels. This could
be addressed through intramitochondrial Ca2+ measurements upon stimulation using Ca2+
-sensitive fluorescent indicator dyes (Vila et al 2003).
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4.4 SV Clusters and Mitochondria are localized in
Pairs
Surprisingly our confocal images with a double staining of SV and Mitochondria revealed
that SV cluster are localized right next to mitochondrial cluster (Fig. 16). In many cases SV
were scattered around a core of mitochondria forming a ring-like structure. Quantification
of the nearest neighbor distances confirmed this observation and showed that this aspect
of spatial organization is not altered in mutant terminals. Similar to our finding, SV has
been described to form donut-like assemblies around a central cluster of mitochondria in
the calyx of Held synapse. Further estimation assume that each of this units consist out
of ∼ 800 synaptic vesicles and six to nine mitochondria (Wimmer et al 2006).
In the calyx of Held this structural specialization appeared with the onset of hearing
which was accompanied by distinct changes in the properties of synaptic transmission.
After the onset of hearing, mature synapses show much less short-term synaptic depression,
low release probabilities, and narrow action potentials (Taschenberger and von Gersdorff,
2000; Taschenberger et al., 2002). It is therefore likely that the pairing from SV clusters
and mitochondria is tightly linked to enhanced synaptic function both in the calyx of Held
and probably also in the NMJ. As a consequence the ATP, produced by mitochondria,
could be directly and more efficiently used for priming, transport, and filling of SVs.
Moreover mitochondria might be perfectly located to fulfill their role as Ca2+ buffer, which
is essential for sustaining high-frequency synaptic transmission. Taken together, we here
show, to our knowledge for the first time at the NMJ, that SV clusters are colocalized with
mitochondria. This provides evidence that the structural principle described in the calyx
of Held might be of more general relevance for pre-synaptic terminals.
4.5 Actin Dynamics in SMA Pathogenesis
The finding, that the SMN protein is involved in the transport of β-actin mRNA along the
axon, raises the question to what extent a disturbance of the actin cytoskelton influences
the pathogenesis in SMA (Rossoll et al 2003).
For our fluorescent microscopy study we labeled β-actin with phalloidin and the postsy-
naptic side with BTX-Rhodamine in TVA muscle at P14. In addition, to gain insight into
the role of β-actin in the organization of SV, we labeled SV with VAChT antibodies. Our
images showed that β-actin is localized in the sub-plasmalemmal region and extends deep
into the cytoplasm forming a thin network. Interestingly, single confocal slices revealed
that -actin surrounds SV clusters forming ring-like structures. Similarly, in the lamprey
giant synapse and hippocampal synaptic terminals actin was described to form ring-like
structures around SV clusters (Shupliakov et al. 2002; Sankaranarayanan et al. 2003).
To our knowledge it is the first time that this organization of actin forming ring-like
structures around SV is described at the NMJ of WT mice and we could show that this
organization pattern was equally found in SMA mice. However the diameter of -actin rings
surrounding SV appeared smaller in mutant than in WT terminals, as could be estimated
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by respective line intensity profiles across SV and phalloidin loops. Moreover, we showed
that in WT mice the area of the terminal covered by phalloidin was apparently larger than
in mutants (WT: 41 ± 9%, n = 6 terminals; mutants: 34 ± 4%, n = 6 terminals). However
this difference did not reach statistical significance (P = 0.5).
A decreased actin content in SMA nerve terminals would be in agreement with the re-
duced β actin protein and mRNA staining in growth cones in culture (Rossoll et al 2003).
Compatible to the proposed function of SMN in the transport of β -actin mRNA along the
axon, it was shown that there is a significant reduction of actin signals in the distal axon,
and growth cone of SMN deficient motor neurons compared to the wild type, whereas in
the soma no significant difference to the wild type has been found (Mayer 2009). In ad-
dition it was shown that treatment of Smn -/-; SMN2 motor neurons in culture by cyclic
adenosinmonophosphate (cAMP) induces increases of SMN protein in the soma, axon, and
growth cones. This could be explained by the presence of a CREII binding element in
the SMN promotor region, which mediates effects of cAMP and therefore stimulates the
SMN-transcription of the examined cells. Interestingly, along with the increase of SMN
protein in cAMP treated SMN -/-; SMN2 motor neuron an increase of the β-actin signal
in the distal axon and growth cone compared to untreated cells was found (Mayer 2009).
This adds further weight to the supposition that a deficit in SMN protein, which underlies
SMA, leads to a disruption of the actin cytoskeleton. Synaptic efficacy depends in multi-
ple ways on the actin cytoskeleton: Using an actin depolymerizing agent, latrunculin A,
it could be shown that actin is essential for the development and maintenance of young
synapses, defined by synaptophysin-labeled vesicle clusters, synaptic vesicle recycling, and
ultrastructure. Also, it is proposed that actin, because it is so highly regulated, is a
principal target for stabilizing or destabilzing signals that ultimately determine synapse
maintenance or elimination (Zhang and Benson 2001). Moreover actin seems to serve as a
molecular scaffold to increase the local concentration of an important regulatory molecule,
synapsin, in the vicinity of the presynaptic vesicle cluster (Sankaranarayanan et al 2003).
Synapsin, a soluble protein of the synaptic terminal, is regulated through phosphoryla-
tion and dephosphorylation. Synapsin forms a link between synaptic vesicles and actin
(Greengard et al 1993). After vesicle fusion, synapsin disassociates from synaptic vesicles
due to its curvature-sensing ALS-motif (Krabben et al 2011). Synapsin then accumulates
in the endocytic region and interacts with a soluble pool of G-actin, where the actin-rich
cytomatrix is formed. Then synapsin reassociates with vesicle membranes (Bloom et al
2003). Together with synapsin actin has been implicated at multiple steps of the synaptic
vesicle cycle, including endocytosis, transport of recycled vesicles to the synaptic vesicle
cluster, and exocytosis (Shupliakov et al 2002).
Regarding this multiple functions of actin in the vesicle cycle it appears plausible that
disorganization in the actin cytoskeleton can affect SV and further neurotransmission.
In the present work we demonstrate that SV clusters remain small during maturation
and the total area of the terminal covered by vesicles is reduced by about 50% in mutant
mice at P14. This is accompanied by a decrease of evoked neurotransmission by 55% and a
two fold reduction of the evoked endplate signals (Kong et al. 2009; Ruiz et al. 2010). Be-
sides the reduction of SV vesicles we could show that mitochondria are organized in clusters
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next to SV clusters at the NMJ. The total area covered by mitochondria per terminal was
∼ 50% reduced in mutants. Axonal transport of mitochondria is ensured by microtubule-
based motors whereas short range movement of vesicles and organelles at growth cones
and nerve terminals depends primarily on actin-myosin-based transport (Langford 2002).
The interaction between microtubule-and actin-based motors suggests that mitochondrial
transport can be coordinated along both cytoskeletal systems (Bridgman 2004). These
tight interactions seem to be controlled through complex phosphorylation processes of mo-
tor proteins, cytoskeletal structures, or mitochondrial membrane proteins (Müller et al
2005).
In conclusion, actin strongly interacts with SV and mitochondria. Also other charac-
teristics of the disease phenotype, like for example reduced axon growth and branching
((Rossoll et al 2003); (Kariya et al 2009)), are highly actin-dependent mechanisms. In-
terestingly, in order to explain the tissue-specific nature of SMA, the only neuron specific
function of the SMN protein which could be identified is that SMN mediates the transport
of β-actin mRNA along the axon. It remains to be determined, whether SMN also medi-
ates the transport of other mRNA species. Above all, further work is required to clarify
whether the characteristics of the disease phenotype described here, such as abnormal SV
clustering and reduction of mitochondria, occur independently or are the consequence of




Proximal spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized
by degeneration of the second motor neurons and progressive paralysis with atrophy of
the proximal muscles. After cystic fibrosis, SMA is the most common autosomal recessive
disorder in humans and the most common genetic cause for infant mortality. SMA, mono-
genic in origin, is caused by a mutation in a single gene, the Survival of Motor Neuron
1 (SMN1) gene, which leads to reduced levels of Survival Motor Neuron (SMN) protein.
SMN is a ubiquitously expressed protein with house-keeping roles in snRNP biogenesis and
pre-mRNA splicing. However, reduced levels of SMN predominantly affect motor neurons
and muscles for reasons that are poorly understood. It was shown that SMN interacts with
β-actin mRNA and mediates its transport along the axon. Functional studies at neuromus-
cular junctions (NMJ) revealed that the evoked neurotransmitter release was decreased by
approximately 55% in most affected muscles, indicating a decreased number of fused vesi-
cles, while asynchronous release is increased by ∼ 300% due to an anomalous accumulation
of intraterminal bulk Ca2+ in SMA mice. A possible explanation of this augmentation is
a decreased Ca2+ reuptake by mitochondria during trains of action potential.
This study presents a comprehensive fluorescent confocal microcopy analysis of the
organization and abundance of synaptic vesicles (SVs), mitochondria, and actin in nerve
terminals of SMA mice (Smn -/-; SMN2; SMN∆). The results are also part of our joint
publication of Torres-Benito L, Neher MF, Cano R, Ruiz R, Tabares L (2011) SMN Require-
ment for Synaptic Vesicle, Active Zone and Microtubule Postnatal Organization in Motor
Nerve Terminals. PlosOne 6(10):e26164.doi:10.1371/journal.pone.0026164. We visualized
SV clusters with an antibody against the vesicular acetylcholine transporter (VAChT) and
could show that in Transversus abdominis (TVA) muscle SV clusters remain small during
maturation with the total area covered by SVs reduced by ∼50%. This severe reduction of
SVs was also found in the caudal band of the Levator auris longus muscle (LAL). However,
only modest abnormalities at the postsynaptic side were detectable in this muscle. This
finding of presynaptic pathology, despite an almost normal postsynaptic status, supports
the hypothesis that SMN-induced changes in muscle cannot be solely attributed to motor
neuron degeneration.
Next, we stained mitochondria with Mito Tracker and found that the area covered by
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mitochondria in mutants was about half compared to wild type. Surprisingly SVs and
mitochondria were strongly colocalized. In many cases a core of mitochondria was clearly
surrounded by a SV rim. This spatial organization was not altered in mutants and might
be of general relevance for the functional integrity in nerve terminals.
Phalloidin stains of F-actin showed that F-actin forms ring-like structures around SV
clusters. These structures and the percentage of the terminal area covered by actin, nor-
malized to the postsynaptic area, were smaller in mutant mice.
Actin is implicated at multiple steps of the synaptic vesicle cycle. Short range movement
of vesicles and organelles, such as mitochondria at growth cones and nerve terminals,
depends primarily on actin-myosin-based transport. Further work is required to clarify
whether the characteristics of the disease phenotype described here, such as abnormal
SV clustering and reduction of mitochondria, occur independently or are the common
consequence of dysfunction of the actin cytoskeleton, which would assign a key role in
SMA pathogenesis to actin.
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from August to October 2012, to the Hospital Italiano, Buenos Aires (Argentina) from
October 2012 to February 2013, and from February to April 2013 to Neu-Mariahilf in
Goettingen. The optional subject, Neurology, I fulfilled at the Klinikum of the University
of Goettingen. In spring 2014 I will prospectively conclude my medical studies.
Publications:
Torres-Benito L, Neher MF, Cano R, Ruiz R, Tabares L (2011)
SMN Requirement for Synaptic Vesicle, Active Zone and Microtubule Postnatal Organiza-
tion in Motor Nerve Terminals
PLoSOne 6(10):e26164.doi:10.1371/journal.pone.002616
